Do analysts prefer PLSE or NNNN?

Pulse Biosciences presently has a consensus price target of $53.20, indicating a potential downside of 1.13%. Given Pulse Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Pulse Biosciences is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulse Biosciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, PLSE or NNNN?

Anbio Biotechnology has higher revenue and earnings than Pulse Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulse Biosciences $350K 10,884.99 -$72.78M -$1.18 N/A Anbio Biotechnology $8.65M 77.52 $6.40M N/A N/A

Does the media refer more to PLSE or NNNN?

In the previous week, Pulse Biosciences had 9 more articles in the media than Anbio Biotechnology. MarketBeat recorded 11 mentions for Pulse Biosciences and 2 mentions for Anbio Biotechnology. Pulse Biosciences' average media sentiment score of 0.35 beat Anbio Biotechnology's score of -0.63 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anbio Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts rate ATRC or NNNN?

AtriCure presently has a consensus price target of $53.30, indicating a potential downside of 4.50%. Given AtriCure's stronger consensus rating and higher probable upside, analysts plainly believe AtriCure is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AtriCure 0 Sell rating(s) 5 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.58 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, ATRC or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than AtriCure. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $569.62M 4.98 -$11.45M $0.21 265.76 Anbio Biotechnology $8.65M 77.52 $6.40M N/A N/A

Does the media refer more to ATRC or NNNN?

In the previous week, AtriCure had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 5 mentions for AtriCure and 2 mentions for Anbio Biotechnology. AtriCure's average media sentiment score of 0.28 beat Anbio Biotechnology's score of -0.63 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anbio Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts prefer TMDX or NNNN?

TransMedics Group currently has a consensus price target of $121.00, indicating a potential upside of 55.39%. Given TransMedics Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe TransMedics Group is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransMedics Group 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, TMDX or NNNN?

TransMedics Group has higher revenue and earnings than Anbio Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 4.44 $190.29M $3.89 20.02 Anbio Biotechnology $8.65M 77.52 $6.40M N/A N/A

Does the media prefer TMDX or NNNN?

In the previous week, TransMedics Group had 12 more articles in the media than Anbio Biotechnology. MarketBeat recorded 14 mentions for TransMedics Group and 2 mentions for Anbio Biotechnology. TransMedics Group's average media sentiment score of 0.46 beat Anbio Biotechnology's score of -0.63 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Anbio Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts prefer BFLY or NNNN?

Butterfly Network currently has a consensus target price of $8.54, suggesting a potential upside of 3.35%. Given Butterfly Network's stronger consensus rating and higher probable upside, equities analysts clearly believe Butterfly Network is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Butterfly Network 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, BFLY or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than Butterfly Network. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Butterfly Network $97.61M 22.55 -$77.06M -$0.29 N/A Anbio Biotechnology $8.65M 77.52 $6.40M N/A N/A

Does the media refer more to BFLY or NNNN?

In the previous week, Butterfly Network had 18 more articles in the media than Anbio Biotechnology. MarketBeat recorded 20 mentions for Butterfly Network and 2 mentions for Anbio Biotechnology. Butterfly Network's average media sentiment score of 0.27 beat Anbio Biotechnology's score of -0.63 indicating that Butterfly Network is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 6 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Anbio Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend NNNN or AXGN?

AxoGen has a consensus price target of $51.70, suggesting a potential upside of 43.09%. Given AxoGen's stronger consensus rating and higher possible upside, analysts clearly believe AxoGen is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 AxoGen 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.79

Which has better valuation & earnings, NNNN or AXGN?

Anbio Biotechnology has higher earnings, but lower revenue than AxoGen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 77.52 $6.40M N/A N/A AxoGen $225.21M 8.62 -$15.70M -$0.68 N/A

Does the media favor NNNN or AXGN?

In the previous week, AxoGen had 9 more articles in the media than Anbio Biotechnology. MarketBeat recorded 11 mentions for AxoGen and 2 mentions for Anbio Biotechnology. AxoGen's average media sentiment score of 0.35 beat Anbio Biotechnology's score of -0.63 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anbio Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative AxoGen 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Anbio Biotechnology (NNNN) Competitors

$4.66 +0.04 (+0.87%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.69 +0.03 (+0.62%)

As of 10/9/2026 07:30 PM Eastern

Compare

NNNN vs. PLSE, ATRC, TMDX, BFLY, and AXGN

Should you buy Anbio Biotechnology stock or one of its competitors? Anbio Biotechnology's main competitors and comparable companies include Pulse Biosciences (PLSE), AtriCure (ATRC), TransMedics Group (TMDX), Butterfly Network (BFLY), and AxoGen (AXGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Anbio Biotechnology compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and Anbio Biotechnology (NASDAQ:NNNN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

77.0% of Pulse Biosciences shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Anbio Biotechnology has higher revenue and earnings than Pulse Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	10,884.99	-$72.78M	-$1.18	N/A
Anbio Biotechnology	$8.65M	77.52	$6.40M	N/A	N/A

In the previous week, Pulse Biosciences had 9 more articles in the media than Anbio Biotechnology. MarketBeat recorded 11 mentions for Pulse Biosciences and 2 mentions for Anbio Biotechnology. Pulse Biosciences' average media sentiment score of 0.35 beat Anbio Biotechnology's score of -0.63 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Anbio Biotechnology has a net margin of 0.00% compared to Pulse Biosciences' net margin of -6,755.78%. Anbio Biotechnology's return on equity of 0.00% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Anbio Biotechnology	N/A	N/A	N/A

Pulse Biosciences presently has a consensus price target of $53.20, indicating a potential downside of 1.13%. Given Pulse Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Pulse Biosciences is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pulse Biosciences has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.31, suggesting that its stock price is 431% more volatile than the broader market.

Summary

Pulse Biosciences beats Anbio Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Anbio Biotechnology compare to AtriCure?

AtriCure (NASDAQ:ATRC) and Anbio Biotechnology (NASDAQ:NNNN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

AtriCure has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.31, suggesting that its stock price is 431% more volatile than the broader market.

AtriCure has a net margin of 1.85% compared to Anbio Biotechnology's net margin of 0.00%. AtriCure's return on equity of 2.34% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Anbio Biotechnology	N/A	N/A	N/A

Anbio Biotechnology has lower revenue, but higher earnings than AtriCure.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$569.62M	4.98	-$11.45M	$0.21	265.76
Anbio Biotechnology	$8.65M	77.52	$6.40M	N/A	N/A

AtriCure presently has a consensus price target of $53.30, indicating a potential downside of 4.50%. Given AtriCure's stronger consensus rating and higher probable upside, analysts plainly believe AtriCure is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

99.1% of AtriCure shares are owned by institutional investors. 4.0% of AtriCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, AtriCure had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 5 mentions for AtriCure and 2 mentions for Anbio Biotechnology. AtriCure's average media sentiment score of 0.28 beat Anbio Biotechnology's score of -0.63 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

AtriCure beats Anbio Biotechnology on 11 of the 14 factors compared between the two stocks.

How does Anbio Biotechnology compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Anbio Biotechnology (NASDAQ:NNNN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

TransMedics Group has higher revenue and earnings than Anbio Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.44	$190.29M	$3.89	20.02
Anbio Biotechnology	$8.65M	77.52	$6.40M	N/A	N/A

99.7% of TransMedics Group shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TransMedics Group has a net margin of 22.69% compared to Anbio Biotechnology's net margin of 0.00%. TransMedics Group's return on equity of 15.88% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
Anbio Biotechnology	N/A	N/A	N/A

TransMedics Group currently has a consensus price target of $121.00, indicating a potential upside of 55.39%. Given TransMedics Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe TransMedics Group is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

TransMedics Group has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.31, indicating that its stock price is 431% more volatile than the broader market.

In the previous week, TransMedics Group had 12 more articles in the media than Anbio Biotechnology. MarketBeat recorded 14 mentions for TransMedics Group and 2 mentions for Anbio Biotechnology. TransMedics Group's average media sentiment score of 0.46 beat Anbio Biotechnology's score of -0.63 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

TransMedics Group beats Anbio Biotechnology on 12 of the 14 factors compared between the two stocks.

How does Anbio Biotechnology compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and Anbio Biotechnology (NASDAQ:NNNN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

37.9% of Butterfly Network shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Butterfly Network currently has a consensus target price of $8.54, suggesting a potential upside of 3.35%. Given Butterfly Network's stronger consensus rating and higher probable upside, equities analysts clearly believe Butterfly Network is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Anbio Biotechnology has lower revenue, but higher earnings than Butterfly Network.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	22.55	-$77.06M	-$0.29	N/A
Anbio Biotechnology	$8.65M	77.52	$6.40M	N/A	N/A

Anbio Biotechnology has a net margin of 0.00% compared to Butterfly Network's net margin of -66.74%. Anbio Biotechnology's return on equity of 0.00% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.99%	-22.96%
Anbio Biotechnology	N/A	N/A	N/A

Butterfly Network has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.31, meaning that its stock price is 431% more volatile than the broader market.

In the previous week, Butterfly Network had 18 more articles in the media than Anbio Biotechnology. MarketBeat recorded 20 mentions for Butterfly Network and 2 mentions for Anbio Biotechnology. Butterfly Network's average media sentiment score of 0.27 beat Anbio Biotechnology's score of -0.63 indicating that Butterfly Network is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	6 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Butterfly Network beats Anbio Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Anbio Biotechnology compare to AxoGen?

Anbio Biotechnology (NASDAQ:NNNN) and AxoGen (NASDAQ:AXGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

AxoGen has a consensus price target of $51.70, suggesting a potential upside of 43.09%. Given AxoGen's stronger consensus rating and higher possible upside, analysts clearly believe AxoGen is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
AxoGen	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

In the previous week, AxoGen had 9 more articles in the media than Anbio Biotechnology. MarketBeat recorded 11 mentions for AxoGen and 2 mentions for Anbio Biotechnology. AxoGen's average media sentiment score of 0.35 beat Anbio Biotechnology's score of -0.63 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
AxoGen	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anbio Biotechnology has a beta of 5.31, indicating that its share price is 431% more volatile than the broader market. Comparatively, AxoGen has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Anbio Biotechnology has higher earnings, but lower revenue than AxoGen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	77.52	$6.40M	N/A	N/A
AxoGen	$225.21M	8.62	-$15.70M	-$0.68	N/A

Anbio Biotechnology has a net margin of 0.00% compared to AxoGen's net margin of -13.36%. Anbio Biotechnology's return on equity of 0.00% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
AxoGen	-13.36%	-8.90%	-6.47%

Summary

AxoGen beats Anbio Biotechnology on 9 of the 15 factors compared between the two stocks.

Get Anbio Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNNN vs. The Competition

Export

Metric	Anbio Biotechnology	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$664.78M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	N/A	25.57	274.15	26.16
Price / Sales	77.52	83.25	635.98	113.06
Price / Cash	103.81	31.87	76.38	53.09
Price / Book	22.19	5.93	11.21	6.34
Net Income	$6.40M	$146.18M	$3.50B	$381.90M
7 Day Performance	-16.04%	-0.38%	-0.90%	-1.41%
1 Month Performance	-28.42%	-2.02%	-4.44%	-3.48%
1 Year Performance	N/A	5.08%	6.96%	1.16%

Anbio Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNNN Anbio Biotechnology	0.5289 of 5 stars	$4.66 +0.9%	N/A	N/A	$664.78M	$8.65M	N/A	27	Analyst Upgrade
PLSE Pulse Biosciences	1.7289 of 5 stars	$50.02 -1.7%	$50.20 +0.4%	+179.5%	$3.55B	$350K	N/A	116	News Coverage Analyst Forecast
ATRC AtriCure	2.4451 of 5 stars	$57.16 -1.5%	$53.30 -6.8%	+53.0%	$2.91B	$534.53M	272.35	1,350	Analyst Upgrade
TMDX TransMedics Group	4.3273 of 5 stars	$82.36 -2.0%	$121.10 +47.0%	-31.1%	$2.85B	$668.47M	21.19	898	News Coverage Analyst Forecast
BFLY Butterfly Network	2.4236 of 5 stars	$9.19 +1.0%	$8.54 -7.1%	+221.0%	$2.45B	$112.14M	N/A	220	News Coverage Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NNNN) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anbio Biotechnology (NNNN) Competitors

NNNN vs. PLSE, ATRC, TMDX, BFLY, and AXGN

How does Anbio Biotechnology compare to Pulse Biosciences?

Summary

How does Anbio Biotechnology compare to AtriCure?

Summary

How does Anbio Biotechnology compare to TransMedics Group?

Summary

How does Anbio Biotechnology compare to Butterfly Network?

Summary

How does Anbio Biotechnology compare to AxoGen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anbio Biotechnology (NNNN) Competitors

NNNN vs. PLSE, ATRC, TMDX, BFLY, and AXGN

How does Anbio Biotechnology compare to Pulse Biosciences?

Do insiders & institutionals hold more shares of PLSE or NNNN?

Which has preferable earnings & valuation, PLSE or NNNN?

Does the media refer more to PLSE or NNNN?

Is PLSE or NNNN more profitable?

Do analysts prefer PLSE or NNNN?

Which has more risk and volatility, PLSE or NNNN?

Summary

How does Anbio Biotechnology compare to AtriCure?

Which has more risk and volatility, ATRC or NNNN?

Is ATRC or NNNN more profitable?

Which has preferable valuation and earnings, ATRC or NNNN?

Do analysts rate ATRC or NNNN?

Do institutionals and insiders believe in ATRC or NNNN?

Does the media refer more to ATRC or NNNN?

Summary

How does Anbio Biotechnology compare to TransMedics Group?

Which has higher valuation & earnings, TMDX or NNNN?

Do institutionals & insiders hold more shares of TMDX or NNNN?

Is TMDX or NNNN more profitable?

Do analysts prefer TMDX or NNNN?

Which has more risk and volatility, TMDX or NNNN?

Does the media prefer TMDX or NNNN?

Summary

How does Anbio Biotechnology compare to Butterfly Network?

Do institutionals and insiders hold more shares of BFLY or NNNN?

Do analysts prefer BFLY or NNNN?

Which has better earnings and valuation, BFLY or NNNN?

Is BFLY or NNNN more profitable?

Which has more volatility and risk, BFLY or NNNN?

Does the media refer more to BFLY or NNNN?

Summary

How does Anbio Biotechnology compare to AxoGen?

Do analysts recommend NNNN or AXGN?

Does the media favor NNNN or AXGN?

Which has more volatility and risk, NNNN or AXGN?

Do insiders and institutionals have more ownership in NNNN or AXGN?

Which has better valuation & earnings, NNNN or AXGN?

Is NNNN or AXGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools